The trial, sponsored by the University of Birmingham, is currently recruiting participants.
Significant infarct progression can make patients ineligible for mechanical thrombectomy.
Risk scores help identify high-risk patients who may benefit from intervention.
Mechanisms including silent cerebral infarct, microemboli, microbleedings, and cerebral hypoperfusion may be responsible for the link between atrial fibrillation and cognitive decline.
The findings support the continuation of high-intensity statin therapy after acute ischemic stroke.
Insulin-resistant patients with ischemic stroke or transient ischemic attack and a high risk of myocardial infarction or recurrent stroke are more likely to derive benefit from pioglitazone than those a lower risk.
There is a reduced risk of adverse events associated with genotype-guided warfarin dosing.
For long-term low-dose aspirin users, there is a 30% increased risk of CVD events with discontinuation of aspirin.
Low-dose oxygen use does not reduce death or disability at 3 months among patients with acute stroke.
A better understanding of characteristics of cerebral lesions may help expedite treatment and improve functional outcomes.
Newer antiepileptic drugs were associated with fewer adverse effects in patients with ischemic stroke.
The investigators noted that rivaroxaban was associated with significantly reduced length of hospital stay compared with warfarin.
The findings align with current guidelines to administer IV tPA regardless of whether or not a patient with ischemic stroke is set to undergo mechanical thrombectomy.
Early supported discharge services may also help care facilities better manage their need for hospital beds and conventional hospital stay costs.
Participants with high baseline levels of SCF had lower all-cause mortality and reduced risk of heart failure, stroke, and myocardial infarction.
There is some evidence that suggests intravenous thrombolysis for stroke may impair the blood-brain barrier and cause cerebral edema.
Brief periods of oxygen deprivation to the brain have been shown to provide neuroprotective effects that reduce stroke infarct size and improve recovery times.
Surprisingly, no evidence was found to suggest that patients with these markers benefit from intensive blood pressure reduction.
The findings may be less applicable to low-volume stroke centers who have less experience in this treatment.
Younger adults who use methamphetamine are at a greater risk for stroke.
The 30-day cumulative incidences of stroke were 2.16% and 0.21% for patients with hip fracture and the general population.
About 1 in 20 patients with VTE have occult cancer detected within a year.
There is no increased risk for stroke for people with thyroid cancer who receive radioiodine therapy.
Investigators found a positive association between higher childhood BMI scores and early adult ischemic stroke.
Hepatitis C virus (HCV) infection may also increase the risk of stroke.
The incidence of intracerebral hemorrhage and subarachnoid hemorrhage was stable in both men and women.
THRIVE scores not only accurately predicted good and poor outcomes in stroke patients following IVT or ET, but also the degree of ischemia following these treatments.
Despite disappointing results, tenecteplase's story in stroke treatment might not be over.
Women and patients of African-American race face an increased risk of experiencing poststroke recrudescence.
There is an increased risk of a recurrent stroke after discontinuing statin therapy 3 to 6 months post initial ischemic stroke.
Neurology Advisor Articles
- Migraine and Gastrointestinal Disorders: Elucidating an Association
- Brain Health in Contact Sports: Putting It All on the Line
- Alzheimer's Disease Risk Similar in Women and Men With APOE ε3/ε4 Genotype
- Non-Invasive Magnetic Device Approved by FDA for Migraine Tx
- FDA Approves Device for Tx of Chronic Pain